Paion Articles
Paion value upgraded on sealing remimazolam deal
9 August 2012
Paion now moving in new direction, analysts note
18 March 2012
Lundbeck buys remaining rights to desmoteplase from Paion
29 February 2012
Showing 1-5 of 5 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
